## David Cibula

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/664012/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Annals of Oncology, 2016, 27, 16-41.	1.2	862
2	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. International Journal of Gynecological Cancer, 2021, 31, 12-39.	2.5	859
3	ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Annals of Oncology, 2019, 30, 672-705.	1.2	665
4	Revised FIGO staging for carcinoma of the cervix uteri. International Journal of Gynecology and Obstetrics, 2019, 145, 129-135.	2.3	612
5	Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncology, The, 2015, 16, 87-97.	10.7	491
6	The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients With Cervical Cancer. International Journal of Gynecological Cancer, 2018, 28, 641-655.	2.5	336
7	The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. Radiotherapy and Oncology, 2018, 127, 404-416.	0.6	241
8	Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer: The Multicenter Intergroup Study DESKTOP II. A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. International Journal of Gynecological Cancer, 2011, 21, 289-295.	2.5	239
9	Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Human Reproduction Update, 2011, 17, 55-67.	10.8	230
10	Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Human Reproduction, 2000, 15, 785-789.	0.9	223
11	Hormonal contraception and risk of cancer. Human Reproduction Update, 2010, 16, 631-650.	10.8	199
12	Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial. Journal of Clinical Oncology, 2020, 38, 1164-1174.	1.6	194
13	Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncology, The, 2021, 22, 609-619.	10.7	186
14	Prognostic significance of low volume sentinel lymph node disease in early-stage cervical cancer. Gynecologic Oncology, 2012, 124, 496-501.	1.4	174
15	SUCCOR study: an international European cohort observational study comparing minimally invasive surgery versus open abdominal radical hysterectomy in patients with stage IB1 cervical cancer. International Journal of Gynecological Cancer, 2020, 30, 1269-1277.	2.5	169
16	2017 Update on the Querleu–Morrow Classification of Radical Hysterectomy. Annals of Surgical Oncology, 2017, 24, 3406-3412.	1.5	162
17	Diagnosis, Treatment, and Follow-Up of Borderline Ovarian Tumors. Oncologist, 2012, 17, 1515-1533.	3.7	161
18	Bone quality assessment in type 2 diabetes mellitus. Osteoporosis International, 2014, 25, 1969-1973.	3.1	151

#	Article	IF	CITATIONS
19	Role of DNA Methylation and Epigenetic Silencing of HAND2 in Endometrial Cancer Development. PLoS Medicine, 2013, 10, e1001551.	8.4	135
20	PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. International Journal of Gynecological Cancer, 2020, 30, 2002-2007.	2.5	135
21	Epigenome-based cancer risk prediction: rationale, opportunities and challenges. Nature Reviews Clinical Oncology, 2018, 15, 292-309.	27.6	129
22	The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 919-936.	2.8	127
23	Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO—The MIMOSA Study. Journal of Clinical Oncology, 2013, 31, 1554-1561.	1.6	126
24	Combined oral contraceptives in the treatment of polycystic ovary syndrome. Human Reproduction Update, 2005, 11, 277-291.	10.8	125
25	The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. Genome Medicine, 2017, 9, 116.	8.2	122
26	European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery. International Journal of Gynecological Cancer, 2017, 27, 1534-1542.	2.5	121
27	Transrectal ultrasound and magnetic resonance imaging in staging of early cervical cancer. International Journal of Gynecological Cancer, 2008, 18, 766-772.	2.5	119
28	Insulin Sensitivity in Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2942-2945.	3.6	115
29	Early-stage cervical cancer: Tumor delineation by magnetic resonance imaging and ultrasound — A European multicenter trial. Gynecologic Oncology, 2013, 128, 449-453.	1.4	115
30	New classification system of radical hysterectomy: Emphasis on a three-dimensional anatomic template for parametrial resection. Gynecologic Oncology, 2011, 122, 264-268.	1.4	112
31	The Dynamics and Prognostic Potential of DNA Methylation Changes at Stem Cell Gene Loci in Women's Cancer. PLoS Genetics, 2012, 8, e1002517.	3.5	111
32	Bilateral ultrastaging of sentinel lymph node in cervical cancer: Lowering the false-negative rate and improving the detection of micrometastasis. Gynecologic Oncology, 2012, 127, 462-466.	1.4	108
33	Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study. Lancet Oncology, The, 2019, 20, 1171-1182.	10.7	108
34	Pregnancy outcome in women with PCOS and in controls matched by age and weight. Human Reproduction, 2003, 18, 1438-1441.	0.9	104
35	European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery. International Journal of Gynecological Cancer, 2016, 26, 1354-1363.	2.5	104
36	ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 153-190.	2.8	99

#	Article	IF	CITATIONS
37	An International Series on Abdominal Radical Trachelectomy: 101 Patients and 28 Pregnancies. International Journal of Gynecological Cancer, 2012, 22, 1251-1257.	2.5	98
38	A prospective study examining the incidence of asymptomatic and symptomatic lymphoceles following lymphadenectomy in patients with gynecological cancer. Gynecologic Oncology, 2015, 137, 291-298.	1.4	98
39	Oral contraceptives and risk of ovarian and breast cancers in <i>BRCA</i> mutation carriers: a meta-analysis. Expert Review of Anticancer Therapy, 2011, 11, 1197-1207.	2.4	96
40	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Radiotherapy and Oncology, 2021, 154, 327-353.	0.6	96
41	Comparison of the Insulin Action Parameters from Hyperinsulinemic Clamps with Homeostasis Model Assessment and QUICKI Indexes in Subjects with Different Endocrine Disorders. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 135-141.	3.6	93
42	The role of androgens in determining acne severity in adult women. British Journal of Dermatology, 2000, 143, 399-404.	1.5	91
43	The EANM clinical and technical guidelines for lymphoscintigraphy and sentinel node localization in gynaecological cancers. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 1463-1477.	6.4	83
44	The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients. Human Reproduction, 2005, 20, 180-184.	0.9	82
45	MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum. Journal of Clinical Oncology, 2020, 38, 3753-3762.	1.6	82
46	Sentinel lymph node (SLN) concept in cervical cancer: Current limitations and unanswered questions. Gynecologic Oncology, 2019, 152, 202-207.	1.4	81
47	High false negative rate of frozen section examination of sentinel lymph nodes in patients with cervical cancer. Gynecologic Oncology, 2013, 129, 384-388.	1.4	80
48	DNA methylation markers for early detection of women's cancer: promise andÂchallenges. Epigenomics, 2014, 6, 311-327.	2.1	76
49	The effects of long-term metformin treatment on adrenal and ovarian steroidogenesis in women with polycystic ovary syndrome. European Journal of Endocrinology, 2001, 144, 619-628.	3.7	73
50	Women's contraceptive practices and sexual behaviour in Europe. European Journal of Contraception and Reproductive Health Care, 2008, 13, 362-375.	1.5	73
51	Abdominal Radical Trachelectomy in Fertility-Sparing Treatment of Early-Stage Cervical Cancer. International Journal of Gynecological Cancer, 2009, 19, 1407-1411.	2.5	71
52	Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2022, 23, 465-478.	10.7	70
53	Sentinel lymph node biopsy in the management of gynecologic cancer. Current Opinion in Obstetrics and Gynecology, 2015, 27, 66-72.	2.0	69
54	Perspectives, fears and expectations of patients with gynaecological cancers during the COVIDâ€19 pandemic: A Panâ€European study of the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe). Cancer Medicine, 2021, 10, 208-219.	2.8	69

#	Article	IF	CITATIONS
55	Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II. Journal of Clinical Oncology, 2021, 39, 3623-3632.	1.6	69
56	Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer. Journal of Clinical Oncology, 2016, 34, 4345-4353.	1.6	68
57	Metabolic syndrome in young Czech women with polycystic ovary syndrome. Human Reproduction, 2005, 20, 3328-3332.	0.9	67
58	Steroid metabolome in fetal and maternal body fluids in human late pregnancy. Journal of Steroid Biochemistry and Molecular Biology, 2010, 122, 114-132.	2.5	66
59	Value of Tertiary Cytoreductive Surgery in Epithelial Ovarian Cancer: An International Multicenter Evaluation. Annals of Surgical Oncology, 2013, 20, 1348-1354.	1.5	64
60	Laparoscopic abdominal radical trachelectomy. Gynecologic Oncology, 2005, 97, 707-709.	1.4	61
61	Pelvic lymphadenectomy in cervical cancer—surgical anatomy and proposal for a new classification system. Gynecologic Oncology, 2010, 116, 33-37.	1.4	61
62	HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: A proof of principle study. International Journal of Cancer, 2009, 125, 2214-2218.	5.1	59
63	A prospective multicenter trial on sentinel lymph node biopsy in patients with early-stage cervical cancer (SENTIX). International Journal of Gynecological Cancer, 2019, 29, 212-215.	2.5	58
64	Circulating levels of pregnanolone isomers during the third trimester of human pregnancy. Journal of Steroid Biochemistry and Molecular Biology, 2007, 105, 166-175.	2.5	56
65	Sentinel lymph node mapping and intraoperative assessment in a prospective, international, multicentre, observational trial of patients with cervical cancer: The SENTIX trial. European Journal of Cancer, 2020, 137, 69-80.	2.8	56
66	Late morbidity following nerve-sparing radical hysterectomy. Gynecologic Oncology, 2010, 116, 506-511.	1.4	54
67	ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors. International Journal of Gynecological Cancer, 2021, 31, 961-982.	2.5	54
68	Ultrasoundâ€guided tru ut biopsy of abdominal and pelvic tumors in gynecology. Ultrasound in Obstetrics and Gynecology, 2010, 36, 767-772.	1.7	53
69	A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival. Genome Medicine, 2014, 6, 47.	8.2	53
70	Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study Journal of Clinical Oncology, 2012, 30, 5001-5001.	1.6	50
71	Low-dose estrogen combined oral contraceptives may negatively influence physiological bone mineral density acquisition during adolescence. European Journal of Endocrinology, 2012, 166, 1003-1011.	3.7	49
72	Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths. Vaccine, 2014, 32, 733-739.	3.8	49

#	Article	IF	CITATIONS
73	Methylation patterns in serum DNA for early identification of disseminated breast cancer. Genome Medicine, 2017, 9, 115.	8.2	49
74	Surgical treatment of "intermediate risk―lymph node negative cervical cancer patients without adjuvant radiotherapy—A retrospective cohort study and review of the literature. Gynecologic Oncology, 2018, 151, 438-443.	1.4	46
75	Laparoscopic radical hysterectomy: a European Society of Gynaecological Oncology (ESCO) statement. International Journal of Gynecological Cancer, 2020, 30, 15-15.	2.5	45
76	Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral contraceptives containing low-androgenic progestin. Human Reproduction, 2002, 17, 76-82.	0.9	44
77	Update on abdominal radical trachelectomy. Gynecologic Oncology, 2008, 111, S111-S115.	1.4	44
78	Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study. Annals of Surgical Oncology, 2017, 24, 2720-2726.	1.5	44
79	The genetic landscape of 87 ovarian germ cell tumors. Gynecologic Oncology, 2018, 151, 61-68.	1.4	44
80	Factors influencing the adoption of the sentinel lymph node technique for endometrial cancer staging: an international survey of gynecologic oncologists. International Journal of Gynecological Cancer, 2019, 29, 60-67.	2.5	43
81	Factors affecting sonographic preoperative local staging of endometrial cancer. Ultrasound in Obstetrics and Gynecology, 2014, 43, 575-585.	1.7	42
82	<scp>ESGO</scp> / <scp>ISUOG</scp> / <scp>IOTA</scp> / <scp>ESGE</scp> Consensus Statement on preoperative diagnosis of ovarian tumors. Ultrasound in Obstetrics and Gynecology, 2021, 58, 148-168.	1.7	42
83	Prediction of Insulin Sensitivity in Nonobese Women with Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 5821-5825.	3.6	41
84	Ultrasound-guided tru-cut biopsy in the management of advanced abdomino-pelvic tumors. International Journal of Gynecological Cancer, 2008, 18, 833-837.	2.5	41
85	Lymphocele: prevalence and management in gynecological malignancies. Expert Review of Anticancer Therapy, 2014, 14, 307-317.	2.4	41
86	Does obesity diminish the positive effect of oral contraceptive treatment on hyperandrogenism in women with polycystic ovarian syndrome?. Human Reproduction, 2001, 16, 940-944.	0.9	40
87	Final results from GCIC/ENGOT/AGOâ€OVAR 12, a randomised placeboâ€controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. International Journal of Cancer, 2020, 146, 439-448.	5.1	40
88	ls insulin resistance an essential component of PCOS?: The influence of confounding factors. Human Reproduction, 2004, 19, 757-759.	0.9	39
89	The relationship between the cervical and anal HPV infection in women with cervical intraepithelial neoplasia. Journal of Clinical Virology, 2014, 59, 18-23.	3.1	39
90	European Society of Gynaecological Oncology quality indicators for surgical treatment of cervical cancer. International Journal of Gynecological Cancer, 2020, 30, 3-14.	2.5	39

#	Article	IF	CITATIONS
91	Neuroactive steroids, their precursors, and polar conjugates during parturition and postpartum in maternal and umbilical blood: 1. identification and simultaneous determination of pregnanolone isomers. Journal of Steroid Biochemistry and Molecular Biology, 2000, 75, 237-244.	2.5	38
92	Underlying mechanisms of ovarian cancer risk reduction after tubal ligation. Acta Obstetricia Et Gynecologica Scandinavica, 2011, 90, 559-563.	2.8	38
93	Relationships of circulating pregnanolone isomers and their polar conjugates to the status of sex, menstrual cycle, and pregnancy. Journal of Endocrinology, 2007, 195, 67-78.	2.6	36
94	SUCCOR cone study: conization before radical hysterectomy. International Journal of Gynecological Cancer, 2022, 32, 117-124.	2.5	36
95	Decreased concentrations of retinol-binding protein 4 in sera of epithelial ovarian cancer patients: A potential biomarker identified by proteomics. Oncology Reports, 2011, 27, 318-24.	2.6	35
96	Risk of micrometastases in non-sentinel pelvic lymph nodes in cervical cancer. Gynecologic Oncology, 2016, 143, 83-86.	1.4	35
97	International radical trachelectomy assessment: IRTA study. International Journal of Gynecological Cancer, 2019, 29, 635-638.	2.5	35
98	ESGO Survey on Current Practice in the Management of Cervical Cancer. International Journal of Gynecological Cancer, 2018, 28, 1226-1231.	2.5	34
99	Diagnostic Accuracy of Ultrasound and MRI in the Mapping of Deep Pelvic Endometriosis Using the International Deep Endometriosis Analysis (IDEA) Consensus. BioMed Research International, 2020, 2020, 1-11.	1.9	34
100	Oncological Outcomes of Nerve-Sparing Radical Hysterectomy for Cervical Cancer: A Systematic Review. Annals of Surgical Oncology, 2015, 22, 3033-3040.	1.5	33
101	Ultrasound in preoperative assessment of pelvic and abdominal spread in patients with ovarian cancer: a prospective study. Ultrasound in Obstetrics and Gynecology, 2017, 49, 263-274.	1.7	33
102	Sentinel node (SLN) biopsy in the management of locally advanced cervical cancer. Gynecologic Oncology, 2009, 115, 46-50.	1.4	32
103	Ultrasound in Gynecological Cancer: Is It Time for Re-evaluation of Its Uses?. Current Oncology Reports, 2015, 17, 28.	4.0	31
104	Prevalence of nonclassic adrenal hyperplasia (NCAH) in hyperandrogenic women. Gynecological Endocrinology, 2008, 24, 154-157.	1.7	30
105	Sexual morbidity following radical hysterectomy for cervical cancer. Expert Review of Anticancer Therapy, 2010, 10, 1037-1042.	2.4	30
106	Pelvic Lymphadenectomy Improves Survival in Patients With Cervical Cancer With Low-Volume Disease in the Sentinel Node: A Retrospective Multicenter Cohort Study. International Journal of Gynecological Cancer, 2014, 24, 303-311.	2.5	30
107	Immunological configuration of ovarian carcinoma: features and impact on disease outcome. , 2021, 9, e002873.		30
108	Neuroactive steroids, their precursors and polar conjugates during parturition and postpartum in maternal blood: 2. Time profiles of pregnanolone isomers. Journal of Steroid Biochemistry and Molecular Biology, 2001, 78, 51-57.	2.5	29

#	Article	IF	CITATIONS
109	Primary pure large-cell neuroendocrine carcinoma of the ovary. Pathology Research and Practice, 2008, 204, 133-137.	2.3	27
110	Completion of radical hysterectomy does not improve survival of patients with cervical cancer and intraoperatively detected lymph node involvement: ABRAX international retrospective cohort study. European Journal of Cancer, 2021, 143, 88-100.	2.8	27
111	Follow-up in Gynecological Malignancies: A State of Art. International Journal of Gynecological Cancer, 2015, 25, 1151-1164.	2.5	26
112	Impact of risk factors on prevalence of anal HPV infection in women with simultaneous cervical lesion. Neoplasma, 2015, 62, 308-314.	1.6	26
113	Validation of ultrasound strategies to assess tumor extension and to predict highâ€risk endometrial cancer in women from the prospective IETA (International Endometrial Tumor Analysis)â€4 cohort. Ultrasound in Obstetrics and Gynecology, 2020, 55, 115-124.	1.7	26
114	Prevalence of insulin resistance and prediction of glucose intolerance and type 2 diabetes mellitus in women with polycystic ovary syndrome. Clinical Chemistry and Laboratory Medicine, 2007, 45, 639-44.	2.3	25
115	Serous tubal intraepithelial carcinoma (STIC) – clinical impact and management. Expert Review of Anticancer Therapy, 2016, 16, 1311-1321.	2.4	25
116	The Diagnostic Accuracy of Ultrasound in Assessment of Myometrial Invasion in Endometrial Cancer: Subjective Assessment versus Objective Techniques. BioMed Research International, 2017, 2017, 1-10.	1.9	25
117	SLN biopsy in cervical cancer patients with tumors larger than 2 cm and 4 cm. Gynecologic Oncology, 2018, 148, 456-460.	1.4	25
118	The best correlation of the new index of hyperandrogenism with the grade of increased body hair. European Journal of Endocrinology, 2000, 143, 405-408.	3.7	24
119	Results of less radical fertility-sparing procedures with omitted parametrectomy for cervical cancer: 5years of experience. Gynecologic Oncology, 2016, 142, 401-404.	1.4	24
120	Laterally Extended Pelvic Resection for Gynaecological Malignancies: A Multicentric Experience with Out-of-the-Box Surgery. Annals of Surgical Oncology, 2019, 26, 523-530.	1.5	24
121	Terms, definitions and measurements to describe sonographic features of lymph nodes: consensus opinion from the Vulvar International Tumor Analysis ( <scp>VITA</scp> ) group. Ultrasound in Obstetrics and Gynecology, 2021, 57, 861-879.	1.7	24
122	Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis. Gynecologic Oncology, 2022, 164, 498-504.	1.4	24
123	Factors Affecting Spontaneous Voiding Recovery After Radical Hysterectomy. International Journal of Gynecological Cancer, 2010, 20, 685-690.	2.5	23
124	Sentinel lymph node status in patients with locally advanced cervical cancers and impact of neoadjuvant chemotherapy. Gynecologic Oncology, 2012, 125, 303-306.	1.4	23
125	Transrectal ultrasound and magnetic resonance imaging in the evaluation of tumor size following neoadjuvant chemotherapy for locally advanced cervical cancer. Ultrasound in Obstetrics and Gynecology, 2013, 42, 705-712.	1.7	23
126	ISUOG Consensus Statement on rationalization of gynecological ultrasound services in context ofÂSARS oVâ€2. Ultrasound in Obstetrics and Gynecology, 2020, 55, 879-885.	1.7	23

#	Article	IF	CITATIONS
127	European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Industry Partners—First Update 2015. International Journal of Gynecological Cancer, 2015, 25, 1328-1330.	2.5	22
128	Clinical impact of low-volume lymph node metastases in early-stage cervical cancer: A comprehensive meta-analysis. Gynecologic Oncology, 2022, 164, 446-454.	1.4	22
129	Role of D327N sex hormone-binding globulin gene polymorphism in the pathogenesis of polycystic ovary syndrome. Journal of Steroid Biochemistry and Molecular Biology, 2007, 104, 68-74.	2.5	21
130	The association of enchondromatosis with malignant transformed chondrosarcoma and ovarian juvenile granulosa cell tumor (Ollier disease). Taiwanese Journal of Obstetrics and Gynecology, 2017, 56, 253-257.	1.3	21
131	The annual recurrence risk model for tailored surveillance strategy inÂpatients with cervical cancer. European Journal of Cancer, 2021, 158, 111-122.	2.8	21
132	The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples. Nature Communications, 2022, 13, 449.	12.8	21
133	Pelvic floor reconstruction by modified rectus abdominis myoperitoneal (MRAM) flap after pelvic exenterations. Gynecologic Oncology, 2017, 144, 558-563.	1.4	20
134	Open vs minimally invasive radical trachelectomy in early-stage cervical cancer: International Radical Trachelectomy Assessment Study. American Journal of Obstetrics and Gynecology, 2022, 226, 97.e1-97.e16.	1.3	20
135	The DNA methylome of cervical cells can predict the presence of ovarian cancer. Nature Communications, 2022, 13, 448.	12.8	20
136	Efficacy and Safety of a Low-Dose 21-Day Combined Oral Contraceptive Containing Ethinylestradiol 20??g and Drospirenone 3mg. Clinical Drug Investigation, 2006, 26, 143-150.	2.2	19
137	Local Control After Tailored Surgical Treatment of Early Cervical Cancer. International Journal of Gynecological Cancer, 2011, 21, 690-698.	2.5	19
138	The Work Place Educational Climate in Gynecological Oncology Fellowships Across Europe: The Impact of Accreditation. International Journal of Gynecological Cancer, 2015, 25, 180-190.	2.5	19
139	Expression, Epigenetic and Genetic Changes of HNF1B in Endometrial Lesions. Pathology and Oncology Research, 2016, 22, 523-530.	1.9	19
140	Oncologic outcome after completing or abandoning (radical) hysterectomy in patients with cervical cancer and intraoperative detection of lymph node positivity; ABRAX (ABandoning RAd hyst in cerviX) Tj ETQqO	0 02:gBT /(	Overbock 10 T
141	Surgical education and training in gynecologic oncology I: European perspective. Gynecologic Oncology, 2009, 114, S52-S55.	1.4	17
142	Trends in stage-specific population-based survival of cancer patients in the Czech Republic in the period 2000–2008. Cancer Epidemiology, 2014, 38, 28-34.	1.9	17
143	Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial. Gynecologic Oncology, 2021, 162, 652-660.	1.4	17
144	A prospective multicenter international single-arm observational study on the oncological safety of the sentinel lymph node algorithm in stage I intermediate-risk endometrial cancer (SELECT, SEntinel) Tj ETQq0 C 1627-1632.	0 rgBT /0	verlock 10 Tf

#	Article	IF	CITATIONS
145	Micrometastases in Sentinel Lymph Nodes Represent a Significant Negative Prognostic Factor in Early-Stage Cervical Cancer: A Single-Institutional Retrospective Cohort Study. Cancers, 2020, 12, 1438.	3.7	16
146	Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial. , 2022, 10, e003190.		16
147	Ultrasonographic appearance of metastatic nonâ€gynecological pelvic tumors. Ultrasound in Obstetrics and Gynecology, 2012, 39, 215-225.	1.7	15
148	Lower-Limb Lymphedema after Sentinel Lymph Node Biopsy in Cervical Cancer Patients. Cancers, 2021, 13, 2360.	3.7	15
149	Neuroactive steroids, their precursors and polar conjugates during parturition and postpartum in maternal and umbilical blood: 3.3β-hydroxy-5-ene steroids. Journal of Steroid Biochemistry and Molecular Biology, 2002, 82, 241-250.	2.5	14
150	High-Risk Human Papillomavirus DNA in the Primary Tumor, Sentinel, and Nonsentinel Pelvic Lymph Nodes in Patients With Early-Stage Cervical Cancer. International Journal of Gynecological Cancer, 2009, 19, 703-707.	2.5	14
151	Uterine Tumors with Neuroectodermal Differentiation. A Report of 4 Cases. Pathology and Oncology Research, 2010, 16, 601-608.	1.9	13
152	Expression of HNF-1β in cervical carcinomas: an immunohistochemical study of 155 cases. Diagnostic Pathology, 2015, 10, 8.	2.0	13
153	What do European women know about their female cancer risks and cancer screening? A cross-sectional online intervention survey in five European countries. BMJ Open, 2018, 8, e023789.	1.9	13
154	European Society of Gynaecological Oncology quality indicators for the surgical treatment of endometrial carcinoma. International Journal of Gynecological Cancer, 2021, 31, 1508-1529.	2.5	13
155	Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents. Trends in Cancer, 2022, 8, 426-444.	7.4	13
156	Impaired Glucose Metabolism in Women with Polycystic Ovary Syndrome. Gynecologic and Obstetric Investigation, 2009, 68, 186-190.	1.6	12
157	Current Clinical Practice in Cytoreductive Surgery for Advanced Ovarian Cancer. International Journal of Gynecological Cancer, 2011, 21, 1.	2.5	12
158	Family planning 2011: better use of existing methods, new strategies and more informed choices for female contraception. Human Reproduction Update, 2012, 18, 670-681.	10.8	12
159	Cancer Antigen 125: Lost to Follow-Up?. International Journal of Gynecological Cancer, 2012, 22, 170-174.	2.5	12
160	A collagen-fibrin patch (Tachosil®) for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: a randomized clinical trial. BMC Cancer, 2014, 14, 635.	2.6	12
161	Synchronous endometrioid endometrial and ovarian carcinomas are biologically related: A clinico‑pathological and molecular (next generation sequencing) study of 22�cases. Oncology Letters, 2019, 17, 2207-2214.	1.8	12
162	A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers Journal of Clinical Oncology, 2014, 32, 5519-5519.	1.6	12

#	Article	IF	CITATIONS
163	Localization of the Sentinel Node of the Upper Outer Breast Quadrant in the Axillary Quadrants. Annals of Surgical Oncology, 2007, 14, 633-637.	1.5	11
164	Preoperative staging of ovarian cancer: comparison between ultrasound, <scp>CT</scp> and wholeâ€body diffusionâ€weighted <scp>MRI</scp> ( <scp>ISAAC</scp> study). Ultrasound in Obstetrics and Gynecology, 2022, 59, 248-262.	1.7	11
165	Post-recurrence survival in patients with cervical cancer. Gynecologic Oncology, 2022, 164, 362-369.	1.4	11
166	Pathologic Protocols for Sentinel Lymph Nodes Ultrastaging in Cervical Cancer. Archives of Pathology and Laboratory Medicine, 2020, 144, 1011-1020.	2.5	10
167	Early Learning Curve in the Assessment of Deep Pelvic Endometriosis for Ultrasound and Magnetic Resonance Imaging. BioMed Research International, 2020, 2020, 1-7.	1.9	10
168	Prospective Evaluation of Ultrasound Accuracy in the Detection of Pelvic Carcinomatosis in Patients with Ovarian Cancer. Ultrasound in Medicine and Biology, 2016, 42, 2196-2202.	1.5	9
169	A collagen-fibrin patch for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: A randomized clinical trial. Gynecologic Oncology, 2018, 149, 140-145.	1.4	9
170	The association among cervical, anal, and oral HPV infections in high-risk and low-risk women. European Journal of Obstetrics and Gynecology and Reproductive Biology: X, 2019, 4, 100061.	1.1	9
171	Impact of sentinel lymph node frozen section evaluation to avoid combined treatment in early-stage cervical cancer. International Journal of Gynecological Cancer, 2020, 30, 744-748.	2.5	9
172	Training in Bowel and Upper Abdominal Surgery in Gynaecological Oncology. International Journal of Gynecological Cancer, 2011, 21, 1.	2.5	9
173	Sensitivity of Follow-Up Methods in Patients After Fertility-Sparing Surgery for Cervical Cancers. International Journal of Gynecological Cancer, 2017, 27, 147-153.	2.5	8
174	Imaging in gynecological disease (19): clinical and ultrasound features of extragastrointestinal stromal tumors ( <scp>eGIST</scp> ). Ultrasound in Obstetrics and Gynecology, 2020, 56, 749-758.	1.7	8
175	Management of pregnancy after fertilityâ€sparing surgery for cervical cancer. Acta Obstetricia Et Gynecologica Scandinavica, 2020, 99, 830-838.	2.8	8
176	Voiding recovery after radical parametrectomy in cervical cancer patients: An international prospective multicentre trial – SENTIX. Gynecologic Oncology, 2021, 160, 729-734.	1.4	8
177	Radical hysterectomy in early cervical cancer in Europe: characteristics, outcomes and evaluation of ESGO quality indicators. International Journal of Gynecological Cancer, 2021, 31, 1212-1219.	2.5	8
178	Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock. Genome Biology, 2022, 23, 52.	8.8	8
179	KEYNOTE-C93/GOG-3064/ENGOT-en15: A phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma Journal of Clinical Oncology, 2022, 40, TPS5623-TPS5623.	1.6	8
180	Outcomes of pregnant patients with Pap smears classified as atypical glandular cells. Cytopathology, 2012, 23, 383-388.	0.7	7

#	Article	IF	CITATIONS
181	Oncological outcome of surgical management in patients with recurrent uterine cancer—a multicenter retrospective cohort study—CEEGOG EX01 Trial. International Journal of Gynecological Cancer, 2019, 29, 711-720.	2.5	7
182	Ultrasound characteristics of a symptomatic and asymptomatic lymphocele after pelvic and/or paraaortic lymphadenectomy. Taiwanese Journal of Obstetrics and Gynecology, 2019, 58, 266-272.	1.3	7
183	Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group survey. International Journal of Gynecological Cancer, 2020, 30, 819-824.	2.5	7
184	Tumour-free distance: a novel prognostic marker in patients with early-stage cervical cancer treated by primary surgery. British Journal of Cancer, 2021, 124, 1121-1129.	6.4	7
185	Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIIb OPINION interim analysis Journal of Clinical Oncology, 2020, 38, 6057-6057.	1.6	7
186	An analysis of the relationship between insulin resistance and the activity of steroid C17,20-lyase and 3β-hydroxysteroid dehydrogenase in ovaries and adrenals in women with polycystic ovary syndrome. Experimental and Clinical Endocrinology and Diabetes, 2000, 108, 455-462.	1.2	6
187	OC132: The role of ultrasound in prediction of optimal vs. suboptimal cytoreductive surgery in advanced ovarian cancers. Ultrasound in Obstetrics and Gynecology, 2008, 32, 286-286.	1.7	6
188	Comparison of corticoid substitution <i>versus</i> combined oral contraception administration in the treatment of non-classic adrenal hyperplasia: A prospective study. Gynecological Endocrinology, 2009, 25, 398-402.	1.7	6
189	ESGO Statement on the Role of CAâ€125 Measurement in Follow-Up of Epithelial Ovarian Cancer. International Journal of Gynecological Cancer, 2012, 22, 175-175.	2.5	6
190	Primary Synovial Sarcoma of the Uterus. Pathology and Oncology Research, 2012, 18, 529-533.	1.9	6
191	SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer Journal of Clinical Oncology, 2021, 39, TPS5610-TPS5610.	1.6	6
192	European Surgical Education and Training in Gynecologic Oncology: The impact of an Accredited Fellowship. International Journal of Gynecological Cancer, 2017, 27, 819-825.	2.5	6
193	Management of patients with intermediate-risk early stage cervical cancer. Journal of Gynecologic Oncology, 2020, 31, e54.	2.2	6
194	Extended pelvic resection for gynecological malignancies: A review of out-of-the-box surgery. Gynecologic Oncology, 2022, , .	1.4	6
195	SUCCOR Risk: Design and Validation of a Recurrence Prediction Index for Early-Stage Cervical Cancer. Annals of Surgical Oncology, 2022, 29, 4819-4829.	1.5	6
196	Quality of life after extended pelvic exenterations. Gynecologic Oncology, 2022, 166, 100-107.	1.4	6
197	Reinstatement of Serum Pregnanolone Isomers and Progesterone During Alcohol Detoxification Therapy in Premenopausal Women. Alcoholism: Clinical and Experimental Research, 2005, 29, 1010-1017.	2.4	5
198	Novel complex genomic rearrangement of the BRCA1 gene. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2008, 637, 205-208.	1.0	5

#	Article	IF	CITATIONS
199	Human Papillomavirus DNA Presence in Pelvic Lymph Nodes in Cervical Cancer. International Journal of Gynecological Cancer, 2010, 20, 126-132.	2.5	5
200	High-risk human papillomavirus DNA in paraaortic lymph nodes in advanced stages of cervical carcinoma. Journal of Clinical Virology, 2011, 50, 46-49.	3.1	5
201	Umbilication Is a Strong Predictor of High-Grade Cervical Intraepithelial Neoplasia. Journal of Lower Genital Tract Disease, 2013, 17, 303-307.	1.9	5
202	Accuracy of ultrasound in prediction of rectosigmoid infiltration in epithelial ovarian cancer. Ultrasound in Obstetrics and Gynecology, 2017, 50, 533-538.	1.7	5
203	Application of International Deep Endometriosis Analysis (IDEA) group consensus in preoperative ultrasound and magnetic resonance imaging of deep pelvic endometriosis. Ultrasound in Obstetrics and Gynecology, 2020, 56, 115-116.	1.7	5
204	Identification of novel HNF1B mRNA splicing variants and their qualitative and semi-quantitative profile in selected healthy and tumour tissues. Scientific Reports, 2020, 10, 6958.	3.3	5
205	Opsalin: A phase II placebo (Pbo)-controlled randomized study of ombrabulin in patients with platinum-sensitive recurrent ovarian cancer (OC) treated with carboplatin (Cb) and paclitaxel (P) Journal of Clinical Oncology, 2013, 31, 5516-5516.	1.6	5
206	Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Interim analysis of a phase 2, open-label, randomized, multicenter trial Journal of Clinical Oncology, 2018, 36, 5509-5509.	1.6	5
207	Quality of training in cervical cancer radical surgery: a survey from the European Network of Young Gynaecologic Oncologists (ENYGO). International Journal of Gynecological Cancer, 2022, 32, 494-501.	2.5	5
208	Comparative analysis of loss of heterozygosity and expression profi le in normal tissue, DCIS and invasive breast cancer. Clinical and Translational Oncology, 2011, 13, 652-655.	2.4	4
209	Hysteroscopic management of displaced levonorgestrelâ€releasing intrauterine system. Journal of Obstetrics and Gynaecology Research, 2013, 39, 1014-1018.	1.3	4
210	Central Pathology Review in SENTIX, a Prospective Observational International Study on Sentinel Lymph Node Biopsy in Patients with Early-Stage Cervical Cancer (ENGOT-CX2). Cancers, 2020, 12, 1115.	3.7	4
211	A comprehensive analysis of the expression, epigenetic and genetic changes of HNF1B and ECI2 in 122Âcases of highâ€grade serous ovarian carcinoma. Oncology Letters, 2021, 21, 185.	1.8	4
212	Postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer: The ENGOT-EN2/DGCG trial Journal of Clinical Oncology, 2017, 35, TPS5613-TPS5613.	1.6	4
213	Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with recurrent epithelial ovarian carcinoma (EOC) after complete response (CR) to 1st-line platinum (Pt)-based ct: Primary analysis of a phase 2, open-label, randomized, multicenter trial Journal of Clinical Oncology, 2018, 36, e17515-e17515.	1.6	4
214	Multiple ovarian biopsy in the treatment of women with polycystic ovary syndrome (PCOS). Clinical and Experimental Obstetrics and Gynecology, 2000, 27, 194-6.	0.2	4
215	Maintenance olaparib in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by somatic (s) or germline (g) BRCA and other homologous recombination repair (HRR) gene mutation status: Overall survival (OS) results from the ORZORA study Journal of Clinical Oncology, 2022, 40, 5519-5519.	1.6	4
216	Abortions and Contraception Use Among Czech and Romanian Women: Comparison of Representative National Studies. Journal of Sexual Medicine, 2011, 8, 1083-1091.	0.6	3

#	Article	IF	CITATIONS
217	Factors influencing decisions about surgical treatment of cervical precancerous lesions. Expert Review of Anticancer Therapy, 2014, 14, 441-451.	2.4	3
218	Robotic and Advanced Laparoscopic Surgical Training in European Gynecological Oncology Trainees. International Journal of Gynecological Cancer, 2017, 27, 375-381.	2.5	3
219	DNA methylation signatures to predict the cervicovaginal microbiome status. Clinical Epigenetics, 2020, 12, 180.	4.1	3
220	Are we better off using multiple endometriosis classifications in imaging and surgery than settle for one universal less than perfect protocol? Review of staging systems in ultrasound, magnetic resonance and surgery. Journal of Obstetrics and Gynaecology, 2021, , 1-7.	0.9	3
221	Subgroup analysis of rucaparib versus chemotherapy as treatment for BRCA-mutated, advanced, relapsed ovarian carcinoma: Effect of platinum sensitivity in the randomized, phase 3 study ARIEL4 Journal of Clinical Oncology, 2021, 39, 5517-5517.	1.6	3
222	Autologous dendritic cell vaccination (DCVAC/OvCa) added to standard of care therapy in three open-label randomized phase 2 studies in women with advanced stage ovarian cancer (OC) Journal of Clinical Oncology, 2014, 32, TPS3134-TPS3134.	1.6	3
223	Challenges in lower limb lymphoedema assessment based on limb volume change: Lessons learnt from the SENTIX prospective multicentre study. Gynecologic Oncology, 2022, 164, 76-84.	1.4	3
224	Comparison of Plasma Osteopontin Levels between Patients with Borderline Ovarian Tumours and Serous Ovarian Carcinoma. Folia Biologica, 2016, 62, 258-262.	0.6	3
225	Exploratory Biochemical Data Analysis: a Comparison of Two Sample Means and Diagnostic Displays. Clinical Chemistry and Laboratory Medicine, 2001, 39, 244-55.	2.3	2
226	OC129: Role of ultrasound in guiding of surgery radicality in cervical cancer management. Ultrasound in Obstetrics and Gynecology, 2008, 32, 285-285.	1.7	2
227	OC27.01: Ultrasound diagnosis of extragenital abdominopelvic tumors. Ultrasound in Obstetrics and Gynecology, 2009, 34, 52-53.	1.7	2
228	Utility and Actual Use of European and Spanish Guidelines on the Management of Endometrial Cancer Among Gynecologic Oncologists in Spain. International Journal of Gynecological Cancer, 2017, 27, 1293-1297.	2.5	2
229	Laterally extended endopelvic resection with external iliac vessels resection and crossover ileofemoral bypass. International Journal of Gynecological Cancer, 2019, 29, 1338-1338.	2.5	2
230	Letter to the editor, Reply to: Cecile Colpaert et al.: Ultrastaging of sentinel lymph nodes in gynecological cancer: Repeating the story of breast cancer?. Gynecologic Oncology Reports, 2019, 28, 94-95.	0.6	2
231	Yolk Sac Tumor of the Omentum: A Case Report and Literature Review. Diagnostics, 2022, 12, 304.	2.6	2
232	Ten years of live surgical broadcast at Charité-MAYO conferences (2010–2019): a systematic evaluation of the surgical outcome. International Journal of Gynecological Cancer, 2022, , ijgc-2021-003173.	2.5	2
233	Low-density lipoprotein receptor–related protein-5 C/T polymorphism in exon 18 is associated with C peptide and proinsulin levels in control women and patients with polycystic ovary syndrome. Fertility and Sterility, 2008, 90, 699-708.	1.0	1
234	OC23.01: Role of ultrasound in the referral of young patients with cervical cancer for fertility sparing surgery. Ultrasound in Obstetrics and Gynecology, 2009, 34, 43-43.	1.7	1

#	Article	IF	CITATIONS
235	Contraceptive behaviour of Czech and Romanian women: comparison of representative national samples. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2011, 154, 163-166.	1.1	1
236	An international series on abdominal trachelectomy: 101 patients and 28 pregnancies. Gynecologic Oncology, 2012, 125, S4.	1.4	1
237	The European Network for Gynaecological Oncological Trial Groups Charta for Privileged Partnership. International Journal of Gynecological Cancer, 2015, 25, 1094-1095.	2.5	1
238	PARP inhibitors in ovarian cancer. British Journal of Cancer, 2015, 113, S1-S2.	6.4	1
239	Ovarian Cancer Screening There May Be Light at the End of the Tunnel?. International Journal of Gynecological Cancer, 2016, 26, 608-609.	2.5	1
240	A Novel Perspective of Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer. Annals of Surgical Oncology, 2016, 23, 2126-2127.	1.5	1
241	Believable or not believable MRAM. Gynecologic Oncology Reports, 2017, 22, 111-112.	0.6	1
242	Are patients and physicians willing to accept less-radical procedures for cervical cancer?. Journal of Gynecologic Oncology, 2018, 29, e50.	2.2	1
243	Modified rectus abdominis myoperitoneal flap for pelvic floor reconstruction. Gynecologic Oncology, 2019, 153, 463-464.	1.4	1
244	Rationale for the avoidance of parametrectomy and systematic lymphadenectomy in patients with early stages of neuroendocrine cervical cancer. International Journal of Gynecological Cancer, 2021, 31, 502-503.	2.5	1
245	Radical Hysterectomy in Cervical Cancer. , 2015, , 353-365.		1
246	A single arm, phase 2, multicenter, international trial of tisotumab vedotin (HuMax-TF-ADC) in previously treated, recurrent or metastatic cervical cancer Journal of Clinical Oncology, 2018, 36, TPS5601-TPS5601.	1.6	1
247	Prediction of insulin sensitivity in non-obese women with polycystic ovary syndrome. Fertility and Sterility, 2002, 78, S279.	1.0	0
248	Prevalence of apoptosis in endometriotic lesions. Fertility and Sterility, 2002, 78, S199-S200.	1.0	0
249	P08.01: Clear cell adenofibroma/fibrocarcinoma of the ovary: ultrasound, macroscopic and histopathologic findings. A case report. Ultrasound in Obstetrics and Gynecology, 2005, 26, 426-426.	1.7	0
250	OC167: Ultrasound-guided tru-cut biopsy in the diagnosis and management of inoperable pelvic tumors. Ultrasound in Obstetrics and Gynecology, 2006, 28, 408-408.	1.7	0
251	Daniel R. Mishell, Jr., M.D., 75 years: A tribute to the master. European Journal of Contraception and Reproductive Health Care, 2006, 11, 59-59.	1.5	0
252	OC229: Ultrasound-guided tru-cut biopsy in the management of advanced abdominopelvic tumors. Ultrasound in Obstetrics and Gynecology, 2007, 30, 437-437.	1.7	0

#	Article	IF	CITATIONS
253	OC231: Transrectal ultrasound (TRUS) and MRI in staging of early cervical cancer. Ultrasound in Obstetrics and Gynecology, 2007, 30, 438-438.	1.7	0
254	OC23.06: Adequacy and safety of ultrasound guided tru-cut biopsy in the management of abdomino-pelvic tumors. Ultrasound in Obstetrics and Gynecology, 2009, 34, 44-45.	1.7	0
255	OC23.07: Analysis of factors influencing tru-cut biopsy sample adequacy in management of abdomino-pelvic masses. Ultrasound in Obstetrics and Gynecology, 2009, 34, 45-45.	1.7	Ο
256	BMD and biochemical markers of bone turnover in adolescent girls on oral contraceptives with different estrogen content. Bone, 2009, 44, S259.	2.9	0
257	Classification system for pelvic lymphadenectomy in cervical cancer. Gynecologic Oncology, 2010, 118, 94-95.	1.4	Ο
258	Late morbidity following nerve-sparing radical hysterectomy. Gynecologic Oncology, 2010, 119, 169-170.	1.4	0
259	Physiological Relevance of Pregnanolone Isomers and Their Polar Conjugates with Respect to the Gender, Menstrual Cycle and Pregnancy. , 2011, , .		Ο
260	OP24.07: Morphological and vascular ultrasound characteristics of pelvic masses of non-gynecological origin. Ultrasound in Obstetrics and Gynecology, 2011, 38, 127-127.	1.7	0
261	Terminology and classification system of radical hysterectomy. Gynecologic Oncology, 2012, 124, 174-175.	1.4	Ο
262	744â€Terms and definitions to describe sonographic features of lymph nodes: consensus opinion from the vulvar international tumor analysis (VITA) group. , 2021, , .		0
263	960â€The annual recurrence risk model for tailored surveillance strategy in cervical cancer patients. , 2021, , .		Ο
264	Polycystic Ovary Syndrome: Implications for Cardiovascular, Endometrial, and Breast Disease. , 2004, , 4-6.		0
265	Pelvic Lymphadenectomy. , 2013, , 83-87.		0
266	P18â€Tumor free distance is the best predictive marker in patients with early-stage cervical cancer treated by primary surgery. , 2019, , .		0
267	Interviews from the European Society of Gynaecological Oncology 2021 Congress: an IJGC-ENYGO Fellows compilation. International Journal of Gynecological Cancer, 2022, 32, 468-473.	2.5	0